Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

NGS may ID SCLC candidates for immunotherapy

SITC 2018

Key clinical point: Next-generation sequencing may help identify small cell lung cancer patients who will benefit from immunotherapy.

Major finding: Median progression-free survival and overall survival were significantly better among tumor mutational burden–high versus tumor mutational burden–low patients (3.3 vs. 1.2 months; hazard ratio, 0.37; and 10.4 vs. 2.5 months; HR, 0.38, respectively).

Study details: A series of 113 patients.

Disclosures: Dr. Ricciuti reported having no disclosures.

Read the article here.

Citation:

SITC 2018

This Week's Must Reads

First-line avelumab/axitinib for RCC benefits wide range of patients, Choueiri TK et al. GUCS 2019, Abstract 544.

QC measures improve with CMS Oncology Care Model, Rocque G et al. J Oncol Pract. 2019. doi: 10. 1200/JOP.18.00390.

Women less likely to receive industry funds, Weng JK et al. JAMA Netw Open. 2019 Jan. 25. doi: 10.1001/jamanetworkopen.2018.7377.

Must Reads in Immuno-oncology